After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
2d
UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...
A small French biotech is trumpeting results from a trial suggesting its developmental drug could be used as part of an HIV cure. The phase 2a trial of AbiVax’s ABX464 pill is small but confirms ...
If future trials go well - now it has passed the first, Phase I, testing hurdle - it could become the longest-acting form of HIV prevention available. Currently, people can take daily pills or ...
The combination of tenofovir, FTC, and efavirenz might soon be available in a single pill. For years, effective antiretroviral treatment has required HIV-positive patients to take a large handful ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback